Challenges in the pharmacogenomic annotation of whole genomes
- PMID: 23708745
- PMCID: PMC4058909
- DOI: 10.1038/clpt.2013.111
Challenges in the pharmacogenomic annotation of whole genomes
Abstract
Next-generation sequencing technologies have enabled the sequencing of an entire genome for less than $4,000. With access to all the genetic variation in an individual, our task will be to use this information to assess the genetic influences on drug efficacy, toxicity, and dosage.
Conflict of interest statement
R.B.A. is a founder of and consultant to Personalis, which focuses on clinical genomics using next-generation sequencing. The other authors declared no conflict of interest.
References
-
- Swen JJ, et al. Pharmacogenetics: from bench to byte–an update of guidelines. Clin. Pharmacol. Ther. 2011;89:662–673. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources